Alternative and complementary treatments for migraine

Tabeeva, G. R.; Filatova, E. G.; Amelin, A. V.; Osipova, V. V.; Artemenko, A. R.; Akhmadeeva, L. R.; Ekusheva, E. V.; Koreshkina, M. I.; Lebedeva, E. R.; Sergeev, A. V.; Golovacheva, V. A.; Latysheva, N. V.; Naprienko, M. V.; Skorobogatykh, K. V.; Azimova, Yu. E.; Rachin, A. P.; Parfenov, V. A.

doi:10.14412/2074-2711-2024-1-4-15

RJTAO

2024

DOI: 10.14412/2074-2711-2024-1-4-15

|View full text |Cite

Alternative and complementary treatments for migraine

G. R. Tabeeva,

E. G. Filatova,

A. V. Amelin

et al.

Abstract: Migraine is a chronic neurological disorder that is associated with considerable disadaptive effect on patients. Despite the development of pharmacotherapy strategies for migraine, only one third of patients are satisfied with their overall treatment. Many migraine patients turn to complementary and alternative medicine (CAM), which is not usually considered a part of conventional medicine and is not always evidence-based. In practise, however, they are often used to improve the effectiveness of standard thera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

References 73 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Refractory migraine

Tabeeva,

Kosivtsova,

Kovalchuk

et al. 2024

RJTAO

View full text Add to dashboard Cite

Many patients with chronic migraine abuse symptomatic medications, have drug-induced headaches, psychiatric comorbidities and respond poorly to conventional preventive therapy. In these cases, the terms “resistant” and “refractory migraine” are used and an expanded therapeutic armamentarium is recommended. Currently, the use of monoclonal antibodies against calcitonin gene-related peptide is the best-studied and most effective method of preventive therapy in resistant migraine cases.

show abstract

Refractory migraine

Tabeeva,

Kosivtsova,

Kovalchuk

et al. 2024

RJTAO

View full text Add to dashboard Cite

show abstract

Analyzing the predictors of relapse in drug-induced headache: a prospective clinical and psychological study

Guziy,

Sergeev,

Tabeeva

2024

RJTAO

Self Cite

View full text Add to dashboard Cite

The prevalence of drug-induced headache (DIHA) in the population is about 7%, and the relapse rate of DIHA after successful treatment is about 40% within 5 years.Objective: to analyze the risk factors for recurrence of DIHA and to develop a prognostic model for the probability of relapse after treatment.Material and methods. The characteristics of 117 patients with DIHA were analyzed on the basis of clinical data and questionnaire data using headache scales (MMAS-8, MIDAS, HALT, HIT-6, mTOQ-5), psycho-emotional profiles (PCS, Spielberger-Hanin Anxiety Scale, PHQ-9, BIS-11, TAS-26, SAGE test, LDQ) that were performed at the time of admission to the clinic and 9 months after the start of therapy. All patients enrolled in the study received a complex treatment that included an educational conversation, “detoxification” and symptomatic therapy during the withdrawal period along with a preventive treatment for chronic migraine (CM).Results. It was shown that there is still a low level of diagnosing of CM and DIHA. By creating a prediction model for the likelihood of recurrence of DIHA, we were able to identify the most important factors for an unfavorable course and recurrence of excessive analgesics use: frequency of analgesic use per day (OR 15.8; 95% C113.1—23.4), degree of alexithymia (score on TAS-26 scale: OR 11.3; 95% CI 6.3—18.1), frequency of combined analgesic use per month (OR 7.1; 95% CI 4.3—11.7), degree of pain catastrophizing on the PCS scale (OR 4.7; 95% CI 1.2—7.3), duration of symptomatic drug abuse (OR 3.2; 95% CI2.1—5.7).Conclusion. A high level of concomitant psychoemotional disorders, especially alexithymia and impulsive behaviour, is a significant risk factor for relapse and should be considered in the treatment of comorbid pathologies. It can be assumed that monoclonal antibodies against calcitonin gene-related peptides, botulinum therapy or combined treatment may be the treatment of choice in cases of ineffective prevention and detoxification attempts in the past as well as in cases of prolonged analgesic abuse.

show abstract

Transcranial direct current stimulation for migrane

Bordovsky,

Andreev,

Zinchenko

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

Migraine is one of the most common primary headache disorders. Nowadays, there is an increase in the prevalence of migraine. It causes a significant reduction in the Quality of Life of those affected. There are two major approaches to treating migraines: attack management and prevention. The concept of primary prophylactic therapy of migraine has developed rapidly. In addition to standard medication, there are increasing data indicating the usefulness and feasibility of non-drug treatments, such as TES (transcranial electrical stimulation). Both cathodal and anodal stimulation have been shown to be effective in migraine treatment: after a course of TES, the number of days per month with headache decreased, the duration and intensity of migraine attacks decreased, and some studies reported a reduction in the number of medications used. O1/O2 (1–2 mA) for cathodal stimulation and F3/F4 (1–2 mA) for anodal stimulation were the most frequently stimulated cortical areas. The average duration of each session was 20 minutes. The length of TES sessions varied from study to study. TES has shown efficacy and safety in treating various forms of migraine. Using this non-invasive method to prevent attacks may be one of the directions for personalizing migraine treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Alternative and complementary treatments for migraine

Cited by 3 publications

References 73 publications

Refractory migraine

Refractory migraine

Analyzing the predictors of relapse in drug-induced headache: a prospective clinical and psychological study

Transcranial direct current stimulation for migrane

Contact Info

Product

Resources

About